血清PCT、CRP、SAA对COPD的评估

Evaluation of Serum PCT, CRP, and SAA for COPD

摘要: 慢性阻塞性肺疾病是常见的疾病，随着人口老龄化的增加，其发病率及死亡率呈逐年增高的趋势，该疾病除气流受限外，还可造成呼吸衰竭、肺动脉高压及慢性肺源性心脏病等并发症，也可使全身其他系统受影响，并且影响患者的日常生活，对社会造成的经济负担重，已成为社会关注的重要问题。近年来许多研究显示，炎症指标包括降钙素原、C反应蛋白、血清淀粉样蛋白A均参与该疾病的炎症反应过程，且对该疾病的严重程度及预后有相关性。单纯的肺功能检查对COPD患者的急性加重风险、严重程度及其预后并不能完全评估。因此，本篇综述现就对PCT、CRP、SAA对COPD的病情严重程度及预后进行评估。

Abstract: Chronic obstructive pulmonary disease is a common disease, with the increase of population aging, the trend of the phase of the morbidity and mortality increased year by year, in addition to the limited airflow, the disease can also cause respiratory failure, pulmonary hypertension, and chronic cor pulmonale and other complications, also can make the whole body other systems affected, and affects the daily life of the patients, causing heavy economic burden to society, has become an important issue of social concern. In recent years, many studies have shown that inflammatory indicators, including procalcitonin, C-reactive protein, and serum amyloid A, are involved in the inflammatory response process of this disease, and are correlated with the severity and prognosis of this disease. Pulmonary function alone cannot fully assess the risk of acute exacerbation, severity, and prognosis in patients with COPD. Therefore, this review is to evaluate the severity and prognosis of PCT, CRP and SAA in COPD.